IBRX250117P3500
- 0.93
- -0.07-7.00%
ImmunityBio Newsroom
ImmunityBio Analyst Ratings
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
ImmunityBio Analyst Ratings
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
ImmunityBio Analyst Ratings
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com
EF Hutton Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $30
EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30
ImmunityBio Price Target Cut to $4.75/Share From $6.00 by Piper Sandler
ImmunityBio Analyst Ratings
Jefferies Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $8
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
Piper Sandler Maintains ImmunityBio(IBRX.US) With Hold Rating, Cuts Target Price to $4.75
Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
ImmunityBio Analyst Ratings
Piper Sandler: Maintaining the ImmunityBio (IBRX.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.
Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Healthcare Services (HCSG) and ImmunityBio (IBRX)